Related Experiment Video
Updated: Oct 2, 2025

A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation
Published on: January 29, 2019
Neutrophil Extracellular Traps in ANCA-Associated Vasculitis and Interstitial Lung Disease: A Scoping Review
Miriana d'Alessandro1, Edoardo Conticini2, Laura Bergantini1
1Respiratory Diseases Unit, Department of Medical and Surgical Sciences & Neurosciences, University of Siena, 53100 Siena, Italy.
Background:
Deregulated neutrophil extracellular traps (NETs) formation is implicated in various diseases, including ANCA-associated vasculitis and pulmonary fibrosis (PF). Lung involvement is frequent in AAV, and interstitial lung diseases (ILDs) are strongly related to MPO-ANCA positivity and mainly reported in microscopic polyangiitis. The association between AAV and ILD is a strong indicator of poor prognosis and limited survival. Neutrophils, ANCA and NET interplay in PF development in AAV. This study aimed to review the literature concerning the implications of NET in lung fibrogenesis specifically focused on AAV associated with ILD, and the potential of NET as a theranostic marker.
Methods:
Through scoping review methodology, we used a descriptive thematic analysis to understand the pathogenic role of NETs in patients with AAV and pulmonary fibrosis and their further role as a theranostic marker of this disease.
Results:
The implications of NET in the pathogenesis of AAV and ILD, as well as an association between these two diseases, have been identified, but the underlying pathophysiological mechanisms are still unknown. The pharmacological or genetic inhibition of NET release reduces disease severity in multiple inflammatory disease models, indicating that NETs are potential therapeutic targets. In this regard, despite the lack of clinical data, we may hypothesise that an optimal management of AAV-ILD patients would require not only B-cells targeted therapy, but also NETs inhibition.
Conclusion:
Preliminary findings seem to display a lack of efficacy of traditional immunosuppressants, such as Rituximab, in this subset of patients, while to date no patients suffering from a definite ILD have been enrolled in clinical trials. Further insights would be provided by their employment, as a combination treatment, in common clinical practice. Although we can imagine that the inhibition of NETs in patients with AAV-ILD could reduce severity and mortality, we still lack the scientific basis that could improve our understanding of the disease from a molecular point of view.
Insights
Neutrophil extracellular traps (NETs) are involved in ANCA-associated vasculitis with interstitial lung disease (AAV-ILD). Inhibiting NETs may offer a new therapeutic strategy for this severe condition, though more research is needed.
Area of Science:
- Immunology
- Pulmonology
- Rheumatology
Background:
- Neutrophil extracellular traps (NETs) formation is implicated in diseases like ANCA-associated vasculitis (AAV) and pulmonary fibrosis (PF).
- Lung involvement, specifically interstitial lung diseases (ILDs), is common in AAV, particularly with MPO-ANCA positivity, and indicates a poor prognosis.
- The interplay between neutrophils, ANCA, and NETs is crucial in the development of PF in AAV.
Purpose of the Study:
- To review the literature on the role of NETs in lung fibrogenesis within the context of AAV-associated ILD.
- To explore the potential of NETs as a theranostic marker for AAV-ILD.
Main Methods:
- Scoping review methodology was employed.
- Descriptive thematic analysis was used to understand the pathogenic role of NETs in AAV and pulmonary fibrosis.
- The role of NETs as a theranostic marker was also investigated.
Main Results:
- NETs play a role in the pathogenesis of AAV and ILD, though mechanisms remain unclear.
- Inhibition of NET release has shown reduced disease severity in inflammatory models, suggesting NETs as therapeutic targets.
- Optimal AAV-ILD management may require B-cell targeted therapy combined with NET inhibition, despite limited clinical data.
Conclusions:
- Traditional immunosuppressants like Rituximab may have limited efficacy in AAV-ILD.
- No patients with definite ILD have been enrolled in clinical trials for NET-targeted therapies.
- Further research is needed to establish the scientific basis for NET inhibition as a treatment to reduce severity and mortality in AAV-ILD.
More Related Videos
11:32Real-Time, High-Throughput Microscopic Quantification of Human Neutrophil Extracellular Trap Release and Assessing the Pharmacology of Antagonists
Published on: October 18, 2024
07:36Author Spotlight: Neutrophil Extracellular Traps Imaging in Human and Mouse Tissues
Published on: August 18, 2023